الفهرس 
Renal cell carcinoma overviewOnly 14 pages are availabe for public view
 |  | from | 190 |  |  |
| | | from | 190 | | |
Abstract
Between November 2012 till December 2014, 30 patients with histologically confirmed advanced RCC were treated with sunitinib at Ain shams clinical oncology department. Medical records were retrospectively reviewed for clinicopathologic characteristics such as age, sex, histology, Eastern Cooperative Oncology group (ECOG) performance statussites of metastasis, laboratory findings, tumor progression and patient survival. Any Eastern Cooperative Oncology group (ECOG) performance status were permitted.both treatment schedule were included. Each patient was classified according to the Memorial Sloan–Kettering Cancer Center (MSKCC) risk scoring system .
methods:
Patients 25 years received oral sunitinib 50 mg per day on a 4-weeks-on–2-weeks-off schedule or on 2weeks on 1 week off schedule . Safety was assessed regularly. Tumour measurements were scheduled per local practice.
results:
A total of 30 patients received sunitinib. Median treatment duration and follow-up were 8 and 13 months. Objective response rate was 34%. Median progression-free survival (PFS) and overall survival (OS) were 9 months and 11months . Median PFS in subgroups of interest: aged 60 years (20%), 8 months; compared to 10 months in age group ≤60 years. Eastern Cooperative Oncology group performance status 0 or 1 (80%), 10 months;compared to 5.5 months in patients with ECOG 2 or 3. LN metastases (40%), 11 months and 8 months in patients with no LN metastasis. The most common grade 3/4 treatment-related adverse events were fatigue (13%), hand and foot syndrome, and anemia (each7%), diarrhea and nausea (each 3%).
conclusion:
Final analysis of the sunitinib reterospective study provided a good opportunity to evaluate the long-term side effects of a tyrosine kinase inhibitor used worldwide in mRCC. Efficacy and safety findings were consistent with previous results.